Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors (MYTHIC)
Étude de phase 1 sur l'innocuité, la pharmacocinétique, la pharmacodynamique et l'activité clinique préliminaire du RP-6306 seul ou en association avec le RP-3500 chez des patients atteints de tumeurs solides avancées
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Phase 1/1b, multi-center, open-label, dose-escalation study to:
- Evaluate the safety profile and MTD of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib when administered orally to establish the recommended Phase 2 dose and schedule
- Characterize the PK and pharmacodynamics of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib
- Assess preliminary anti-tumor activity associated with lunresertib alone and in combination with RP-3500 or in combination with zedoresertib
This study was previously posted by Repare Therapeutics. In September 2025, sponsorship of the trial was transferred to Debiopharm International S.A
Expanded Access Status: There is no expanded access program available for the investigational products in this study at this time.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Debiopharm International S.A
- Numéro de téléphone: +41 21 321 01 11
- E-mail: clinicaltrials@debiopharm.com
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Complété
- #2002, The Hospital for Sick Children
-
Toronto, Ontario, Canada, M5G 2C1
- Recrutement
- #2001, Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Complété
- #2003, The Research Institute of the McGill University Health Centre
-
-
-
-
-
Copenhagen, Danemark
- Recrutement
- #4001, Rigshospitalet - Blegdamsvej
-
-
-
-
-
Madrid, Espagne, 28027
- Pas encore de recrutement
- Clinica Universidad de Navarra
-
Madrid, Espagne, 28050
- Recrutement
- Hospital Universitario HM Sanchinarro
-
Madrid, Espagne, 28040
- Recrutement
- START Madrid. Hospital Fundación Jimenez Diaz
-
Navarra, Espagne, 31008
- Pas encore de recrutement
- Clinica Universidad de Navarra
-
-
-
-
-
London, Royaume-Uni, W1G 6AD
- Recrutement
- #3003, Sarah Cannon Research Institute
-
-
-
-
California
-
Los Angeles, California, États-Unis, 90095
- Complété
- # 1019, UCLA, Westwood Cancer Center
-
San Francisco, California, États-Unis, 94158
- Recrutement
- #1025, University of California San Francisco
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06520
- Recrutement
- #1012, Yale
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32224
- Recrutement
- #1017, Mayo Clinic
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- #1002, Dana Farber Cancer Institute
-
-
Michigan
-
Grand Rapids, Michigan, États-Unis, 49503
- Recrutement
- #1023, START Midwest
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55902
- Recrutement
- #1016, Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63130
- Recrutement
- #1011, Washington University
-
-
New York
-
New Hyde Park, New York, États-Unis, 11042
- Recrutement
- #1032, Northwell Health Cancer Institute
-
New York, New York, États-Unis, 10065
- Recrutement
- #1004, Memorial Sloan Kettering Cancer Institute
-
New York, New York, États-Unis, 10032
- Complété
- #1008, Columbia University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Complété
- #1010, University of Pennsylvania
-
-
Rhode Island
-
Providence, Rhode Island, États-Unis, 02903
- Recrutement
- #1007, Rhode Island Hospital
-
Providence, Rhode Island, États-Unis, 02903
- Recrutement
- #1030, Women & Infants Hospital of Rhode Island
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- #1001, The University of Texas M.D. Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Recrutement
- #1013, The University of Utah
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22903
- Recrutement
- #1027, University of Virginia
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female and ≥12 years-of-age at the time of informed consent.
- Lansky performance status ≥50% for patients ≤16 years of age, or ECOG score of 0, 1, (or 2 for module 1) for patients >16 years of age.
- Locally advanced or metastatic resistant or refractory solid tumors.
- Patients <18 years of age must weigh at least 40 kg.
- Submission of available tumor tissue at screening or willingness to have a biopsy performed if safe and feasible
- Next generation sequencing (NGS) report obtained in a CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarker.
- CCNE1 amplification (non-equivocal) as determined by either a tumor or plasma NGS test, or FISH
- FBXW7 deleterious mutations identified by either a tumor or plasma NGS test
- PPP2R1A deleterious mutations identified by either a tumor or plasma NGS test
- Measurable disease as per RECIST v1.1. For certain modules, patients with prostate cancer or ovarian cancer that have non-measurable disease but have elevated tumor markers (PSA or CA-125, respectively) can also be eligible
- Ability to swallow and retain oral medications.
- Acceptable hematologic and organ function at screening.
- Negative pregnancy test (serum) for women of childbearing potential (WOCBP) at Screening.
- Resolution of all toxicities of prior therapy or surgical procedures.
- Any prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment.
Exclusion Criteria:
- Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half-lives, whichever is shorter, prior to first dose of study drug.
- History or current condition, therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment.
- Patients who are pregnant or breastfeeding.
- Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety.
- Major surgery within 4 weeks prior to first dose of lunresertib.
- Uncontrolled, symptomatic brain metastases.
- Uncontrolled hypertension.
- Certain prior anti-cancer therapy
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Phase 1: Lunresertib Single-Agent, Dose Escalation and Food-effect Study
Patients receive lunresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor |
|
Expérimental: Phase 1: Lunresertib in combination with RP-3500, Dose Escalation Study
Patients receive lunresertib with RP-3500 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor Oral ATR Inhibitor |
|
Expérimental: Phase 1: Lunresertib in combination with Zedoresertib, Dose Escalation Study
Patients receive lunresertib with zedoresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor Oral WEE1 Inhibitor
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety and Tolerability of lunresertib either in monotherapy or in combination with RP-3500 or with Zedoresertib in patients with eligible advanced solid tumors
Délai: Up to 90 days after last administration of study intervention
|
Assessed by treatment-emergent adverse events (TEAEs), physical examinations (PEs), safety laboratory assessments, electrocardiograms (ECGs), and vital sign measurements |
Up to 90 days after last administration of study intervention
|
|
To define the MTD of lunresertib monotherapy, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
Délai: Up to 90 days after last administration of study intervention
|
Assessed by the incidence of Dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
|
To define the MTD of lunresertib in combination with RP-3500 or in combination with Zedoresertib, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
Délai: Up to 90 days after last administration of study intervention
|
Assessed by the incidence of dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
|
The relative bioavailability of lunresertib capsule formulation as compared to lunresertib tablet formulation in the fasted state
Délai: Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
Assessed by the plasma concentrations of lunresertib with calculation of pharmacokinetic (PK) parameters including maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), area under the plasma concentration-time curve (AUC) , for both formulations in the fasted state. |
Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
|
The effect of food on the PK of tablet formulation of lunresertib when administered in fed conditions compared to administration under fasted conditions
Délai: Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
Assessed by the plasma concentrations of lunresertib with calculation of the ratio of PK parameters (e.g., Cmax and AUC) between the tablet formulation under fasted and fed state. |
Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
|
To assess the safety and tolerability of lunresertib tablets in combination with RP-3500, confirm the MTD of lunresertib tablets in combination with RP-3500, and determine a RP2D and preferred schedule
Délai: Up to 90 days after last administration of study intervention
|
Assessed by DLTs, TEAEs, safety laboratory assessments, the incidence of DLTs and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The plasma concentrations of lunresertib monotherapy (capsule formulation) in the fasted and fed states
Délai: Up to 90 days after last administration of study intervention
|
Assessed by the plasma concentrations of lunresertib with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate |
Up to 90 days after last administration of study intervention
|
|
To assess the relationship between pharmacodynamic biomarkers and PK of lunresertib at different dose levels and/or schedules
Délai: Up to 90 days after last administration of study intervention
|
Assessed by evaluation of biomarkers in pre- and on-treatment biopsies, and circulating tumor DNA (ctDNA) dynamics during treatment |
Up to 90 days after last administration of study intervention
|
|
The plasma concentrations of lunresertib and RP-3500 when dosed in combination
Délai: Up to 90 days after last administration of study intervention
|
Assessed by the plasma concentrations of lunresertib and RP-3500 with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate for each analyte |
Up to 90 days after last administration of study intervention
|
|
To assess preliminary anti-tumor activity achieved with lunresertib monotherapy, lunresertib in combination with RP-3500 or lunresertib in combination with Zedoresertib
Délai: Through Study Completion, an average of 1 year
|
Measured by best percent change in tumor size from baseline, objective response rate (ORR), overall response rate, tumor marker response, duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS). |
Through Study Completion, an average of 1 year
|
|
To assess the safety and anti-tumor effects of lunresertib capsule + RP-3500
Délai: Through Study Completion, an average of 1 year
|
As measure by TEAEs, safety laboratory assessments, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS |
Through Study Completion, an average of 1 year
|
|
To further characterize the PK of lunresertib tablets and assess preliminary anti-tumor
Délai: Through Study Completion, an average of 1 year
|
Measured by Plasma concentrations of lunresertib with calculation of Cmax, Tmax, AUC, elimination t1/2, and other PK parameters as appropriate, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS |
Through Study Completion, an average of 1 year
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- Debio 0123-106
- RP-6306-01 (Autre identifiant: Repare Therapeutics)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .